Pra Health (PRAH) Stock Price, Quote, News and Overview
NASDAQ:PRAH - Nasdaq -
PRAH Quote, Performance and Key Statistics
165.21
-2.8 (-1.67%)
The current stock price of PRAH is 165.21 null. In the past month the price decreased by -2.76%. In the past year, price increased by 73.81%.
PRAH Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 24.36 | 203.70B | ||
| DHR | DANAHER CORP | 28.07 | 151.18B | ||
| A | AGILENT TECHNOLOGIES INC | 25.59 | 38.62B | ||
| IQV | IQVIA HOLDINGS INC | 17.15 | 33.64B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 31.26 | 26.91B | ||
| WAT | WATERS CORP | 31.58 | 22.26B | ||
| ICLR | ICON PLC | 14.39 | 16.63B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 31.25 | 15.27B | ||
| ILMN | ILLUMINA INC | 38.45 | 14.94B | ||
| RVTY | REVVITY INC | 23.23 | 13.85B | ||
| AVTR | AVANTOR INC | 17.3 | 11.78B | ||
| TEM | TEMPUS AI INC | N/A | 10.72B |
Related stock screener links
About PRAH
Company Profile
PRA Health Sciences, Inc. engages in the provision of outsourced clinical development services to the biotechnology and pharmaceutical industries. The company is headquartered in Raleigh, North Carolina and currently employs 18,100 full-time employees. The company went IPO on 2014-11-13. The firm provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The firm offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases. Its services include data management, statistical analysis, clinical trial management, and regulatory and drug development consulting. The company provides its clients with clinical development service offerings, which includes both traditional, project-based Phase I through Phase IV services, as well as embedded and functional outsourcing services. As of December 31, 2016, its clinical development platform included approximately 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East. The firm's service offerings include product registration, strategic solutions and early development services.
Company Info
Pra Health
4130 Parklake Ave Ste 400
Raleigh NORTH CAROLINA 27612 US
CEO: Colin Shannon
Employees: 18100.0
Company Website: http://www.prahs.com
Phone: 19197868200.0
Pra Health / PRAH FAQ
What is the stock price of Pra Health today?
The current stock price of PRAH is 165.21 null. The price decreased by -1.67% in the last trading session.
What is the ticker symbol for Pra Health stock?
The exchange symbol of Pra Health is PRAH and it is listed on the Nasdaq exchange.
On which exchange is PRAH stock listed?
PRAH stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for Pra Health stock?
4 analysts have analysed PRAH and the average price target is 171.11 null. This implies a price increase of 3.57% is expected in the next year compared to the current price of 165.21. Check the Pra Health stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is Pra Health worth?
Pra Health (PRAH) has a market capitalization of 10.70B null. This makes PRAH a Large Cap stock.
How many employees does Pra Health have?
Pra Health (PRAH) currently has 18100.0 employees.
What are the support and resistance levels for Pra Health (PRAH) stock?
Pra Health (PRAH) has a support level at 165.2 and a resistance level at 165.66. Check the full technical report for a detailed analysis of PRAH support and resistance levels.
Is Pra Health (PRAH) expected to grow?
The Revenue of Pra Health (PRAH) is expected to grow by 19.32% in the next year. Check the estimates tab for more information on the PRAH EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy Pra Health (PRAH) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PRAH, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PRAH, evaluating the profitability, health, valuation and growth aspects
- Pra Health (PRAH) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- Pra Health (PRAH) Sales and EPS estimates to see what analysts future expectations are.
- Pra Health (PRAH) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- Pra Health (PRAH) Insider and Institutional Ownership to learn about the owners and their transactions.
- Pra Health (PRAH) Stock Chart to make your own analysis
- Pra Health (PRAH) Latest news and press-releases to stay up to date.
Does Pra Health (PRAH) stock pay dividends?
PRAH does not pay a dividend.
When does Pra Health (PRAH) report earnings?
Pra Health (PRAH) will report earnings on 2022-03-01, after the market close.
What is the Price/Earnings (PE) ratio of Pra Health (PRAH)?
The PE ratio for Pra Health (PRAH) is 32.65. This is based on the reported non-GAAP earnings per share of 5.06 and the current share price of 165.21 null. Check the full fundamental report for a full analysis of the valuation metrics for PRAH.
PRAH Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to PRAH. When comparing the yearly performance of all stocks, PRAH is one of the better performing stocks in the market, outperforming 77.96% of all stocks.
PRAH Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to PRAH. While PRAH is still in line with the averages on profitability rating, there are concerns on its financial health.
PRAH Financial Highlights
Over the last trailing twelve months PRAH reported a non-GAAP Earnings per Share(EPS) of 5.06. The EPS decreased by -1.36% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 6.4% | ||
| ROA | 4.98% | ||
| ROE | 13.71% | ||
| Debt/Equity | 0.74 |
PRAH Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 60% to PRAH. The Buy consensus is the average rating of analysts ratings from 4 analysts.
For the next year, analysts expect an EPS growth of 29.21% and a revenue growth 19.32% for PRAH